2.64
-0.06 (-2.22%)
| Previous Close | 2.70 |
| Volume | 9,525 |
| Price / Sales | 4.29 |
| Price / Book | 1.24 |
| 52 Weeks Range |
| Operating Margin (TTM) | -19,230.14% |
| Diluted EPS (TTM) | -1.47 |
| Quarterly Revenue Growth (YOY) | -28.60% |
| Total Debt/Equity (MRQ) | 0.42% |
| Current Ratio (MRQ) | 2.24 |
| Operating Cash Flow (TTM) | -8.69 M |
| Levered Free Cash Flow (TTM) | -3.84 M |
| Return on Assets (TTM) | -54.16% |
| Return on Equity (TTM) | -117.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BioRestorative Therapies, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -1.17 |
|
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 25.54% |
| % Held by Institutions | 12.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wealth Alliance, Llc | 30 Jun 2026 | 2,000 |
| Keystone Financial Group | 30 Jun 2026 | 1,430 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |